Last week, a group of 55 U.S. physicians sent a letter to the U.S. Food & Drug Administration (FDA), urging the agency not to approve the use of Gilead's HIV/AIDS treatment drug Truvada for use as an HIV prevention pill - also known as "pre-exposure prophylaxis" (PrEP). In the letter, spearheaded by AIDS Healthcare Foundation (AHF), the physicians detail a number of concerns raised by first-in humans efficacy data emerging from the iPrEX study of Truvada to prevent HIV transmission.
A pill that has long been used to treat HIV has moved one step closer to becoming the first drug approved to prevent healthy people from becoming infected with the virus that causes AIDS. The Food and Drug Administration said Tuesda... Read Post
Doctors now have another weapon against HIV/AIDS in their arsenal, and it’s a potent one. For the first time, the U.S. Food and Drug Administration (FDA) approved a drug treatment that will prevent infection in healthy people. The d... Read Post